Mérieux Développement Announces Equity Financing into Xeris Pharmaceuticals

Lyon, France and Boston (ots/PRNewswire) -

Mérieux Développement has recently concluded an equity investment
into Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical
company focused on the development and commercialization of novel
formulations of injectable drugs. With this additional financing,
Xeris Pharmaceuticals expects to fund registration trials and the
commercial launch of Xeris' lead product, G-Pen(TM) a novel glucagon
injection for treatment of severe hypoglycemia, as well as clinical
validation of novel products leveraging Xeris' unique formulation
platform.

"I very much appreciate the insights and connections which Mérieux
Développement has brought to us over the last few months," said Paul
Edick, President and CEO of Xeris Pharmaceuticals, Inc. He continued:
"We look forward to receiving additional contribution from our
premier investors, to help further advance Xeris' portfolio and
commercial strategy in the US and internationally."

François Valencony, General Manager of Mérieux Développement,
added : "Xeris' team has unique capabilities and know-how allowing
them to develop products which we think can deliver substantial
value to diabetes patients and healthcare systems globally, including
the first soluble, stable, ready-to-inject glucagon for use by people
with diabetes and other indications with currently high unmet medical
needs."

About Xeris Pharmaceuticals, Inc. - http://www.xerispharma.com

Xeris is an Austin, Texas-based, specialty biopharmaceutical
company developing improved and differentiated injectable
therapeutics for multiple indications including diabetes. The
company's proprietary XeriSol(TM) and XeriJect(TM) formulation
technologies allow for the subcutaneous and intradermal delivery of
highly concentrated, non-aqueous, ready-to-inject formulations of
peptides, proteins, antibodies and small molecules using
auto-injectors, multi-dose pens and pumps. Xeris' proprietary
formulation platforms have the potential to offer distinct advantages
over existing products and formulations including: up to 1000-fold
lower injection volumes, long term room-temperature stability,
elimination of reconstitution and refrigeration, all of which can
lead to products that are easier to use by patients, caregivers,
health practitioners, and can reduce costs for payers and the
healthcare system.

About Mérieux Développement - http://www.merieux-developpement.com

Mérieux Développement is the investment fund of Institut Mérieux
specialized in venture capital and growth equity transactions in the
healthcare and nutrition sectors. Mérieux Développement supports
entrepreneurs and companies with products or services presenting
worldwide innovation to Health. Mérieux Développement brings its
expertise and international network to enable entrepreneurs to
disrupt and create new markets. Mérieux Développement is an affiliate
of Institut Mérieux, which employs around 16,000 employees worldwide,
with consolidated revenues exceeding 2.5 billion Euros in 2016.

Contact communication - MxD North America L.L.C.

Alix SIPAHI - communication@merieux-developpement.com - tel:
+1-617-679-8000

ots Originaltext: Merieux Developpement
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Merieux Developpement, übermittelt durch news aktuell